Refractory anemia
Drug research and approvals for refractory anemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 60 studies of refractory anemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 2 approved and 0 open orphan designations naming it.
- Recruiting worldwide: 60
- Trials authorized in Canada: 0
- FDA orphan approvals: 2
- EU medicines: 0
- Combination Therapy With Danazol, Prednisolone, and Thalidomide for Thalidomide-Refractory Transfusion-Dependent…NCT07884773 · Phase 3 · Khyber Medical University Peshawar · starts Oct 12, 2026
- F182112 in Relapsed/Refractory Autoimmune Hemolytic AnemiaNCT07816341 · Phase 1 · Institute of Hematology & Blood Diseases Hospital, China · starts Oct 27, 2026
- PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDSNCT07761533 · Phase 1 / Phase 2 · Chaser Therapeutics, Inc. · starts Sep 8, 2025
- Phase I/II Study of Anti-CD38 Monoclonal Antibody in Refractory Severe Aplastic AnemiaNCT07714512 · Phase 1 / Phase 2 · Institute of Hematology & Blood Diseases Hospital, China · starts Jun 30, 2026
- A Phase 1/2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure SyndromesNCT07712562 · Phase 1 / Phase 2 · Dren Bio · starts Aug 14, 2026
- Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDSNCT07607418 · Phase 2 · Ruijin Hospital · starts May 22, 2026
- Haplo-Cord HSCT for AML/MDSNCT07588360 · Not applicable · Fujian Medical University Union Hospital · starts Oct 20, 2025
- Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune DiseaseNCT07549698 · Phase 1 / Phase 2 · CRISPR Therapeutics AG · starts Jul 17, 2026
- Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Risk AML/MDSNCT07532824 · Phase 1 / Phase 2 · Institute of Hematology and Blood Transfusion, Czech Republic · starts Nov 21, 2025
Phase 3 11
- CytarabineDNA inhibitor
- IdarubicinDNA topoisomerase II alpha inhibitor
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- BusulfanDNA inhibitor
- DaunorubicinDNA topoisomerase II alpha inhibitor
- MethotrexateDihydrofolate reductase inhibitor
- AldesleukinInterleukin-2 receptor agonist
- DexamethasoneGlucocorticoid receptor agonist
- ThioguanineInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- CyclophosphamideDNA inhibitor
- AsparaginaseAsparagine hydrolytic enzyme
Phase 2 1
How its trials ended
65 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 21 whose ending is known, 48% met their primary endpoint, 10% missed it and 43% stopped early.
- Completed, result not reported3655%
- Met its primary endpoint1015%
- Ongoing58%
- Stopped: funding58%
- Status unknown35%
- Missed its primary endpoint23%
- Stopped: other or unclear23%
- Stopped: safety12%
- Stopped: sponsor or business decision12%
| May 2, 2006 | DacogenFor treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all… | Otsuka Pharmaceutical Development | Approved |
| May 19, 2004 | VidazaTreatment of patients with the following myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts… | Celgene Corporation | Approved |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA